BR112018074147A2 - tratamento de doenças colestáticas intra-hepáticas - Google Patents

tratamento de doenças colestáticas intra-hepáticas

Info

Publication number
BR112018074147A2
BR112018074147A2 BR112018074147-7A BR112018074147A BR112018074147A2 BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2 BR 112018074147 A BR112018074147 A BR 112018074147A BR 112018074147 A2 BR112018074147 A2 BR 112018074147A2
Authority
BR
Brazil
Prior art keywords
treatment
intrahepatic cholestatic
cholestatic diseases
diseases
intrahepatic
Prior art date
Application number
BR112018074147-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Boudes Pol
A. Mcwherter Charles
Original Assignee
Cymabay Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cymabay Therapeutics, Inc. filed Critical Cymabay Therapeutics, Inc.
Publication of BR112018074147A2 publication Critical patent/BR112018074147A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018074147-7A 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas BR112018074147A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662343688P 2016-05-31 2016-05-31
US62/343,688 2016-05-31
PCT/US2017/029620 WO2017209865A1 (en) 2016-05-31 2017-04-26 Treatment of intrahepatic cholestatic diseases

Publications (1)

Publication Number Publication Date
BR112018074147A2 true BR112018074147A2 (pt) 2019-03-06

Family

ID=58699276

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018074147-7A BR112018074147A2 (pt) 2016-05-31 2017-04-26 tratamento de doenças colestáticas intra-hepáticas

Country Status (27)

Country Link
US (5) US10272058B2 (https=)
EP (1) EP3463328B1 (https=)
JP (1) JP7079735B2 (https=)
KR (1) KR102408288B1 (https=)
CN (2) CN121466055A (https=)
AU (1) AU2017274293B2 (https=)
BR (1) BR112018074147A2 (https=)
CA (1) CA3024155C (https=)
CY (1) CY1125465T1 (https=)
DK (1) DK3463328T3 (https=)
ES (1) ES2921230T3 (https=)
HR (1) HRP20220903T1 (https=)
HU (1) HUE059838T2 (https=)
IL (1) IL263372B2 (https=)
LT (1) LT3463328T (https=)
MX (1) MX390417B (https=)
NZ (1) NZ748721A (https=)
PL (1) PL3463328T3 (https=)
PT (1) PT3463328T (https=)
RS (1) RS63345B1 (https=)
RU (1) RU2765460C2 (https=)
SG (1) SG11201810123SA (https=)
SI (1) SI3463328T1 (https=)
SM (1) SMT202200471T1 (https=)
UA (1) UA122719C2 (https=)
WO (1) WO2017209865A1 (https=)
ZA (1) ZA201808360B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
EP3880185A1 (en) * 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash
US20220241228A1 (en) 2021-02-01 2022-08-04 Cymabay Therapeutics, Inc. Treatment of cholangiopathies
WO2024180642A1 (ja) 2023-02-28 2024-09-06 株式会社日立ハイテク プラズマ処理装置およびプラズマ処理装置の試料台の製造方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7101993B1 (en) 1990-01-11 2006-09-05 Isis Pharmaceuticals, Inc. Oligonucleotides containing 2′-O-modified purines
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
WO1996027606A1 (en) 1995-03-06 1996-09-12 Isis Pharmaceuticals, Inc. Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom
US6166197A (en) 1995-03-06 2000-12-26 Isis Pharmaceuticals, Inc. Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions
NZ331217A (en) 1996-02-14 2000-02-28 Novartis Ag Sugar-modified gapped oligonucleotides for eliciting RNase H activity for strand cleavage in an opposing strand
US5883109A (en) 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6066653A (en) 1997-01-17 2000-05-23 Bristol-Myers Squibb Co. Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7511131B2 (en) 2002-11-13 2009-03-31 Genzyme Corporation Antisense modulation of apolipoprotein B expression
US7981915B2 (en) 2003-04-30 2011-07-19 Beth Israel Deaconess Medical Center Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene
WO2005042478A2 (en) 2003-09-19 2005-05-12 Janssen Pharmaceutica, N.V. 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs
KR101494067B1 (ko) 2004-03-05 2015-02-16 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 부작용을 최소화하면서 과지질혈증 및 과콜레스테롤혈증과 연관된 질환 또는 질병의 치료 방법
JO3006B1 (ar) 2005-09-14 2016-09-05 Janssen Pharmaceutica Nv املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك
CA2740874C (en) 2008-10-17 2018-02-27 Metabolex, Inc. Use of ppar.gamma.agonists to reduce small dense ldl particles
SG175390A1 (en) * 2009-04-29 2011-12-29 Amarin Corp Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
NZ602125A (en) 2010-03-30 2014-01-31 Novartis Ag Uses of dgat1 inhibitors
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20160279085A1 (en) 2013-11-20 2016-09-29 Cymabay Therapeutics, Inc. Treatment of Severe Hyperlipidemia
HK1224186A1 (zh) 2013-11-20 2017-08-18 Cymabay Therapeutics, Inc. 纯阖家族型高胆固醇血症的治疗
RS57970B1 (sr) 2014-03-20 2019-01-31 Cymabay Therapeutics Inc Tretman intrahepatičkih holestatskih oboljenja
US10272058B2 (en) 2014-03-20 2019-04-30 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
KR102374499B1 (ko) 2014-04-11 2022-03-14 사이머베이 쎄라퓨틱스, 인코퍼레이티드 Nafld 및 nash 의 치료
EP3160458A1 (en) 2014-06-26 2017-05-03 Cymabay Therapeutics, Inc. Treatment of severe hypertriglyceridemia
US10512622B2 (en) 2017-07-14 2019-12-24 Cymabay Therapeutics, Inc. Treatment of intrahepatic cholestatic diseases
DK3973959T3 (da) 2017-09-26 2025-01-20 Cymabay Therapeutics Inc Behandling af kolestatisk kløe med seladelpar
EP3880187A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Treatment of obesity and its complications
EP3880185A1 (en) 2018-11-16 2021-09-22 CymaBay Therapeutics, Inc. Combination treatment of nafld and nash

Also Published As

Publication number Publication date
PT3463328T (pt) 2022-07-07
RU2018146504A (ru) 2020-07-09
US20210000774A1 (en) 2021-01-07
JP2019518022A (ja) 2019-06-27
HRP20220903T1 (hr) 2022-10-14
CY1125465T1 (el) 2025-05-09
US20200061006A1 (en) 2020-02-27
CN121466055A (zh) 2026-02-06
SG11201810123SA (en) 2018-12-28
JP7079735B2 (ja) 2022-06-02
US20190255004A1 (en) 2019-08-22
CA3024155C (en) 2023-10-10
KR102408288B1 (ko) 2022-06-10
PL3463328T3 (pl) 2022-10-03
US20210220305A1 (en) 2021-07-22
WO2017209865A1 (en) 2017-12-07
MX2018014915A (es) 2019-04-24
AU2017274293A1 (en) 2018-12-13
EP3463328A1 (en) 2019-04-10
RU2765460C2 (ru) 2022-01-31
RU2018146504A3 (https=) 2020-07-27
HUE059838T2 (hu) 2023-01-28
AU2017274293B2 (en) 2022-03-31
US20170340589A1 (en) 2017-11-30
SMT202200471T1 (it) 2023-01-13
SI3463328T1 (sl) 2022-08-31
LT3463328T (lt) 2022-08-10
ES2921230T3 (es) 2022-08-22
CN109195594A (zh) 2019-01-11
US10272058B2 (en) 2019-04-30
MX390417B (es) 2025-03-20
UA122719C2 (uk) 2020-12-28
IL263372B2 (en) 2023-06-01
RS63345B1 (sr) 2022-07-29
DK3463328T3 (da) 2022-07-04
US11000494B2 (en) 2021-05-11
ZA201808360B (en) 2020-02-26
US10813895B2 (en) 2020-10-27
US11596614B2 (en) 2023-03-07
EP3463328B1 (en) 2022-06-15
US10478411B2 (en) 2019-11-19
CA3024155A1 (en) 2017-12-07
KR20190015363A (ko) 2019-02-13
NZ748721A (en) 2022-04-29
IL263372A (en) 2018-12-31

Similar Documents

Publication Publication Date Title
MX2020007273A (es) Tratamiento del prurito colestasico.
BR112018074147A2 (pt) tratamento de doenças colestáticas intra-hepáticas
LT3416631T (lt) Terapiniai agentai, skirti neurodegeneracinių ligų gydymui
MX369921B (es) Tratamiento de la hgna y ehna.
EA201691887A1 (ru) Лечение внутрипеченочных холестатических заболеваний
BR112018077492A2 (pt) métodos de tratamento de câncer de ovário
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
HUE041940T2 (hu) MRNS-terápia szembetegségek kezelésére
PT3086637T (pt) Animais não humanos com um gene de cluster de diferenciação 47 humanizado
HRP20181194T1 (hr) Farmaceutski pripravci za liječenje bolesti posredovanih transmembranskim regulatorom provodljivosti cistične fibroze
EP3448263A4 (en) ELECTROTHERAPEUTIC TREATMENT
DK3212233T3 (da) Kombinationsterapi til behandling af sygdom
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA42930A (fr) Traitement de maladies neurodégénératives
MA40607B1 (fr) Traitements médicaux à base d'anamoréline
EA201892265A1 (ru) Способы лечения офтальмологических заболеваний
HRP20190595T1 (hr) Ventil za primjenu terapije s više lijekova u obliku tekućina
SI3565592T1 (sl) Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
LT3352857T (lt) T-dm1 atsparių, vėžiu sergančių pacientų gydymas junginiu syd985
IL259381B (en) Mirabegron for the treatment of retinal diseases
PL3903774T3 (pl) N,n-bis-2-merkaptoetyloizoftalamid do leczenia chorób neurodegeneracyjnych

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]